Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): An observational nationwide study applying linkage between DANBIO and national registries

Bente Glintborg*, Stylianos Georgiadis, Anne Gitte Loft, Asta Linauskas, Hanne Lindegaard, Oliver Hendricks, Dorte V. Jensen, Birgitte Lange Andersen, Kamilla Danebod, Anders Villumsen, Grith Eng, Charlotte Wiell, Natalia Manilo, Salome Kristensen, Johnny Raun, Jolanta Grydehøj, Stavros Chrysidis, Mette Nørgaard, Frank Mehnert, Niels Steen KroghMerete Lund Hetland

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Original languageEnglish
JournalAnnals of the rheumatic diseases
Volume79
Issue number6
Pages (from-to)846-848
ISSN0003-4967
DOIs
Publication statusPublished - Jun 2020

Keywords

  • Anti-TNF
  • DMARDs (biologic)
  • epidemiology
  • rheumatoid arthritis

Cite this